Vaccines: Risk for Long COVID and Vaccine Doses
A study found that 2 or 3 doses of the COVID-19 vaccine reduced the rate of long COVID among Italian health care workers.
Tag: vaccines
All
Latest
All
Latest
How Long Are Vaccinated People with SARS-CoV-2 Infectious?
To examine the infectious periods in vaccinated individuals infected with the SARS-CoV-2 Omicron and Delta variants, researchers collected daily PCR tests from a group of college students and staff.
All
Latest
Moderna’s Bivalent Booster Candidate Shows Superior Antibody Response to Omicron
A 50 µg dose of Moderna's bivalent booster candidate, mRNA-1273.214, demonstrated superior neutralizing antibody response against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.
Pfizer-BioNTech Vaccine Study Looks at Healthcare Cost-Savings
The health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in a new study in the peer-reviewed Journal of Medical Economics.
Read More
COVID Vaccine Induces Multiple Immune Responses
While COVID vaccine-induced neutralizing antibody responses protect against SARS-CoV-2 infection, control of viral replication is mediated by responses that involve T cells and the antibody-binding Fc receptor.
Read More
FDA Limits Use of J&J Janssen COVID-19 Vaccine
The FDA limited authorized use of the J&J Janssen COVID-19 vaccine to certain individuals due to risk of thrombosis with thrombocytopenia syndrome.
Read More
NIH to Evaluate Second COVID Booster in Adults
A Phase 2 clinical trial to evaluate second COVID booster shots has begun enrolling adult participants in the United States. The COVID-19 Variant Immunologic Landscape (COVAIL) trial, sponsored by the NIAID, aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.
Read More
Pfizer Submits Pediatric COVID Booster for Authorization
Pfizer Inc and BioNTech SE have submitted an application for US FDA authorization of a 10-µg booster dose of its pediatric COVID booster for children age 5 through 11 years old.
Read More
Moderna Developing Bivalent COVID Vaccine Booster
Moderna’s first bivalent COVID vaccine booster candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron.
Read More
Clinical Trial Will Study Allergic Reactions to COVID Vaccines
A clinical trial by the NIAID will study rare but potentially serious systemic allergic reactions to COVID vaccines.
Read More
Skin Bacteria May Boost Immune Response of Smallpox Vaccine
A large increase in skin bacteria in mice inoculated with the smallpox vaccine may enhance the immune response, according to a study published in Plos Pathogens.
Read More
Positive Data for Pfizer Pediatric Booster
A 10-µg dose (third dose) of the Pfizer pediatric booster in healthy children age 5 through 11...
Read More
CoVac-1 COVID Vaccine May Provide Protection for Cancer Patients with B-cell Deficiencies
The novel CoVac-1 COVID vaccine induced T-cell immune responses in 93% of patients with B-cell deficiencies, including many patients with leukemia and lymphoma.
Read More
A Highly-Accurate 30-second COVID Test?
Researchers at the University of Florida and National Yang Ming Chiao Tung University in Taiwan have developed a 30-second COVID test that can detect coronavirus infection in as sensitively and accurately as the gold standard PCR test.
Read More
Third COVID Vaccine Increased Immune Response in Multiple Myeloma Patients
A third COVID vaccine dose benefitted most immunocompromised people with a blood cancer called multiple myeloma, according to a fast-tracked study in Cancer Cell.
Read More